Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome
复制标题
DOI：
10.1002/mds.21500
复制
发表时间：
2007-06-15
影响因子：
8.6
通讯作者：
Pezzoli, Gianni
中科院分区：
文献类型：
--
作者：
Antonini, Angelo;Isaias, Ioannis U.;Pezzoli, Gianni
我们前瞻性评估了9例帕金森病（PD; H&Y >= 3）患者的临床和生活质量变化，这些患者伴有严重的运动波动和运动障碍，通过经皮内镜胃造口术开始持续每日左旋多巴十二指肠输注。7例患者完成了随访期。所有患者的“休息”时间和致残性运动障碍时间均明显缩短（P < 0.01）。左旋多巴的每日总剂量与基线剂量没有差异。在“开启”状态下，患者的日常生活活动能力（ADRS-II）和运动并发症（-IV）以及PDQ-39的四个领域（活动能力、日常生活活动能力、耻辱感、身体不适; P < 0.05）均有显著改善。2例患者因不良事件退出研究。我们的研究结果表明，一个令人满意的治疗窗口可以实现并维持几个月的晚期PD患者。(c)2007年，《社会运动》创刊。
We assessed prospectively clinical and quality of life changes in 9 patients with Parkinson's disease (PD; H&Y >= 3) with severe motor fluctuations and dyskinesia who started continuous daily levodopa duodenal infusion through percutaneous endoscopic gastrostomy. Seven patients completed the follow-up period. Duration of "off" periods and time with disabling dyskinesia shortened significantly in all patients (P < 0.01). Total daily dose of levodopa infused did not differ from baseline equivalents. There were significant improvements in UPDRS-II (activities of daily living) and -IV (motor complications) in the "on" condition (P < 0.02), and in four PDQ-39 domains (mobility, activities of daily living, stigma, bodily discomfort; P < 0.05). Two patients withdrew for adverse events. Our results demonstrate that a satisfactory therapeutic window can be achieved and maintained for several months in advanced PD patients. (c) 2007 Movement Disorder Society.